Screener
Tarsus Pharmaceuticals, Inc. TARS Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s accounts receivable?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accounts receivable of $96.03M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accounts receivable changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accounts receivable increased by 64.6% year-over-year, from $58.33M to $96.03M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accounts receivable?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s accounts receivable has grown at a 82.7% compound annual growth rate (CAGR), from $25M to $278.44M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude